Keybank National Association OH Purchases New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Keybank National Association OH bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 307,689 shares of the medical equipment provider's stock, valued at approximately $27,526,000. Keybank National Association OH owned 0.44% of Lantheus as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Torray Investment Partners LLC boosted its position in shares of Lantheus by 17.0% during the fourth quarter. Torray Investment Partners LLC now owns 19,166 shares of the medical equipment provider's stock worth $1,715,000 after purchasing an additional 2,788 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of Lantheus by 108.3% during the fourth quarter. Jones Financial Companies Lllp now owns 2,273 shares of the medical equipment provider's stock worth $203,000 after purchasing an additional 1,182 shares in the last quarter. Bridges Investment Management Inc. boosted its position in shares of Lantheus by 98.9% during the fourth quarter. Bridges Investment Management Inc. now owns 12,070 shares of the medical equipment provider's stock worth $1,080,000 after purchasing an additional 6,001 shares in the last quarter. Chase Investment Counsel Corp bought a new position in shares of Lantheus during the fourth quarter worth $1,431,000. Finally, Parkside Financial Bank & Trust boosted its position in shares of Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after purchasing an additional 280 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Remove Ads

Analysts Set New Price Targets

LNTH has been the topic of a number of recent analyst reports. Truist Financial lifted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $132.86.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.

Lantheus Price Performance

LNTH stock traded up $6.11 during midday trading on Friday, hitting $106.34. The company's stock had a trading volume of 1,369,851 shares, compared to its average volume of 921,738. Lantheus Holdings, Inc. has a twelve month low of $56.44 and a twelve month high of $126.89. The company's fifty day moving average price is $90.43 and its 200 day moving average price is $96.80. The stock has a market capitalization of $7.28 billion, a P/E ratio of 17.69 and a beta of 0.44.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.